» Articles » PMID: 26364556

The Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Lupus Erythematosus: A General Population-based Study

Overview
Specialty Rheumatology
Date 2015 Sep 15
PMID 26364556
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate the future risk and time trends of newly diagnosed venous thromboembolism (VTE) in individuals with incident systemic lupus erythematosus (SLE) in the general population.

Methods: Using a population-based database that includes all residents of British Columbia, Canada we conducted a study cohort of all patients with incident SLE and up to 10 age-, sex-, and entry-time-matched individuals from the general population. We compared incidence rates of pulmonary embolism (PE), deep venous thrombosis (DVT), and VTE between the two groups according to SLE disease duration. We calculated hazards ratios (HR), adjusting for confounders.

Results: Among 4863 individuals with SLE (86% female; mean age, 48.9 years), the incidence rates (IRs) of PE, DVT, and VTE were 2.58, 3.33, and 5.32 per 1000 person-years, respectively, whereas the corresponding rates in the comparison cohort were 0.67, 0.57, and 1.11 per 1000 person-years. Compared with non-SLE individuals, the multivariable HRs among SLE patients were 3.04 (95% CI: 2.08-4.45), 4.46 (95% CI: 3.11-6.41), and 3.55 (95% CI: 2.69-4.69), respectively. The age-, sex-, and entry-time-matched HRs for PE, DVT, and VTE were highest during the first year after SLE diagnosis [13.57 (95% CI: 7.66-24.02), 11.13 (95% CI: 6.55-18.90), and 12.89 (95% CI: 8.56-19.41), respectively].

Conclusion: These findings provide population-based evidence that patients with SLE have a substantially increased risk of VTE, especially in the first year after SLE diagnosis. Awareness and increased vigilance of this potentially fatal, but preventable, complication is recommended.

Citing Articles

Recurrent pulmonary thromboembolism with cardiac tamponade as initial manifestations of lupus and antiphospholipid syndrome: a case report.

Villanueva-Valle J, Amaro-Palomo E, Munive-Eyssautier M, Gonzalez-Diaz F, Sotelo-Soleno A, Alba-Valencia S Arch Peru Cardiol Cir Cardiovasc. 2025; 5(4):237-242.

PMID: 39850341 PMC: 11753424. DOI: 10.47487/apcyccv.v5i4.418.


Thoracic manifestations of rheumatic disease: a radiologist's view.

De Clercq A, Jans L, Gosselin R, Delrue L, Vereecke E, Parkar A Ther Adv Musculoskelet Dis. 2024; 16:1759720X241293943.

PMID: 39620048 PMC: 11605741. DOI: 10.1177/1759720X241293943.


Clinical Characteristics and Prognosis of Acute Pulmonary Embolism with Hemoptysis in Autoimmune Disease Patients.

Li Y, Yang J, Xue P, Zhang T, Sun X, Peng M Int J Med Sci. 2024; 21(8):1399-1407.

PMID: 38903924 PMC: 11186428. DOI: 10.7150/ijms.94052.


Long-term incidence, risk factors and complications for venous thromboembolism in patients with systemic lupus erythematosus.

Nossent J, Keen H, Preen D, Inderjeeth C Lupus. 2024; 33(8):787-796.

PMID: 38655753 PMC: 11141078. DOI: 10.1177/09612033241247359.


Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.

Jiang W, Jia W, Dong C Thromb J. 2024; 22(1):34.

PMID: 38576023 PMC: 10993540. DOI: 10.1186/s12959-024-00599-3.


References
1.
del Rincon I, Williams K, Stern M, Freeman G, Escalante A . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2002; 44(12):2737-45. DOI: 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-%23. View

2.
Bursac Z, Gauss C, Williams D, Hosmer D . Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008; 3:17. PMC: 2633005. DOI: 10.1186/1751-0473-3-17. View

3.
Mok C, Ho L, Yu K, To C . Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2010; 29(6):599-604. DOI: 10.1007/s10067-009-1364-z. View

4.
Cervera R, Khamashta M, Font J, Sebastiani G, Gil A, Lavilla P . Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82(5):299-308. DOI: 10.1097/01.md.0000091181.93122.55. View

5.
Ramagopalan S, Wotton C, Handel A, Yeates D, Goldacre M . Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011; 9:1. PMC: 3025873. DOI: 10.1186/1741-7015-9-1. View